Johnson & Johnson to showcase industry-leading neuropsychiatry innovations at the 2025 Psych Congress Annual Meeting

Core Insights - Johnson & Johnson is presenting 21 abstracts at the U.S. Psychiatric and Mental Health Congress, focusing on major depressive disorder, treatment-resistant depression, and schizophrenia [1][4] - The company emphasizes its commitment to advancing neuroscience and improving patient outcomes through innovative treatments [2][4] Group 1: Major Depressive Disorder (MDD) - MDD affects approximately 332 million people globally, representing about 5% of the population, with around 21 million adults in the U.S. experiencing at least one major depressive episode in 2021 [7][8] - Current treatments often fail to address the unique symptoms of MDD, with 2 in 3 patients continuing to experience residual symptoms despite standard care [7][8] - Insomnia is a common symptom in MDD, affecting about 60% of patients, which can worsen the quality of life and increase the risk of relapse [8] Group 2: Treatment-Resistant Depression (TRD) - Approximately one-third of adults with MDD are classified as having TRD, defined as inadequate response to two or more oral antidepressants [9][10] - The economic burden of TRD is significant, with many patients cycling through multiple medications without achieving remission [10] - The STAR*d study indicates that after trying a third oral antidepressant, about 86% of patients do not achieve remission [10] Group 3: Innovative Treatments - Seltorexant is an investigational therapy being studied as an adjunctive treatment for MDD with insomnia symptoms, aiming to normalize orexin-2 receptor overactivation [13] - CAPLYTA (lumateperone) is approved for treating schizophrenia and bipolar depression, with a supplemental new drug application under review for its use in MDD [11][12] - SPRAVATO (esketamine) is approved for TRD and MDD with suicidal ideation, having been administered to over 150,000 patients worldwide [12][13] Group 4: Schizophrenia Portfolio - Johnson & Johnson offers a comprehensive portfolio of schizophrenia therapies, including long-acting injectables like INVEGA SUSTENNA, INVEGA TRINZA, and INVEGA HAFYERA [14][36] - These treatments provide various dosing options and are designed to support individual patient needs [14][36]